Interaction between CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, and its ligand CD40L, a 39-kDa glycoprotein, is essential for the development of humoral and cellular immune responses 1,2 . Selective blockade or activation of this pathway provides the ground for the development of new treatments against immunologically based diseases 3,4 and malignancies 5, 6 . Like other members of the TNF superfamily, CD40L monomers self-assemble around a threefold symmetry axis to form noncovalent homotrimers that can each bind three receptor molecules 7, 8 . Here, we report on the structure-based design of small synthetic molecules with C 3 symmetry that can mimic CD40L homotrimers. These molecules interact with CD40, compete with the binding of CD40L to CD40, and reproduce, to a certain extent, the functional properties of the much larger homotrimeric soluble CD40L. Architectures based on rigid C 3 -symmetric cores may thus represent a general approach to mimicking homotrimers of the TNF superfamily.
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CD40L is expressed mainly on activated T cells, whereas its cognate receptor, CD40, is constitutively expressed on dendritic cells (DC), macrophages and B cells. The engagement of CD40 by its ligand contributes to regulation of B cell proliferation, immunoglobulin production, immunoglobulin class switching, germinal center formation and development of B cell memory 1 . Moreover, CD40-CD40L interaction has an essential role in cellular immune response in which CD40 ligation activates DCs, 'licensing' them to present antigen to cytotoxic T cells by increasing MHC and costimulatory molecule expression and by producing high levels of IL-12, a T cell-stimulating cytokine [9] [10] [11] . Antibodies against CD40 with agonist activity have been used to increase immune response in infectious diseases 12, 13 and in cancer immunotherapy 5, 6 . All of these results underscore the important therapeutic applications that could emerge from the development of small-molecule CD40 agonists.
Although ligand-induced dimerization is a general mechanism for activating receptors of cytokines and growth factors 14 , signaling through receptors of the TNFR superfamily strongly relies on the formation of stoichiometrically defined C 3 -symmetric complexes 7 . The structures of several TNF family members in complex with their cognate receptors show that each ligand homotrimer interacts with three monomeric receptor chains 7, 15, 16 . The geometry of the resulting 3:3 hexameric complex is favorable to the formation of an internal 3:3 signaling complex between the intracellular tail of the receptor and transduction proteins, ultimately activating downstream effector pathways 7 .
Despite the difficulty in identifying small molecules that can disrupt protein-protein interactions, synthetic agonists of homodimeric cytokine receptors have been reported 17, 18 . The ability of these molecules to dimerize cell-surface receptors is a major determinant of their effector functions 19 . In the present study, we have developed CD40L mimetics by integrating threefold symmetry as a design principle. We reasoned that such trimeric architectures, besides providing the correct geometry for receptor trimerization, could also achieve tight binding to CD40 with receptor-binding elements of low surface areas (for example, small peptides) 20, 21 . Although the CD40L-CD40 interaction has not been determined at the atomic level, a model of the complex built using the X-ray structure of CD40L and a homology model of CD40 (ref. 22 ) has provided the basis for the structure-based design of trivalent ligands (Fig. 1a) . Both rigid, flat macrocyclic (D,L-a-hexapeptide and b 3 -tripeptide) and flexible branched C 3 -symmetric scaffolds have been considered as core structures to distribute receptor-binding elements with geometry and distances that could match those of the CD40L homotrimer (Fig. 1b) . Five 'hot spot' residues in CD40L (namely, Lys143, Tyr145, Tyr146 (in the AA¢¢ loop), Arg203 (in the DE loop) and Gln220 (in the F strand)) have been previously identified using a combination of molecular modeling and site-directed mutagenesis 22, 23 . Mutations of these CD40L surface residues markedly affect binding to CD40. On the basis of these considerations, the small CD40-interacting © 2005 Nature Publishing Group http://www.nature.com/naturechemicalbiology region Lys143-Gly-Tyr-Tyr146 of CD40L was selected as a CD40-binding motif and tethered via an amino hexanoic acid (Ahx) residue spacer to the central core structures to give compounds 1-3 (Fig. 1b) .
To determine whether the resulting trimeric ligands interact with CD40, we performed a series of surface plasmon resonance (SPR) experiments using a recombinant human CD40-mouse immunoglobulin (hCD40:mIg) immobilized on the sensor chip via an anti-mouse Fc or 5C3 an anti-human CD40 monoclonal antibody (anti-hCD40 mAb; Fig. 2 and Supplementary Fig. 1 online) . We mixed a fixed amount of recombinant human soluble CD40L tethered to a mouse CD8 tail (hCD40L:CD8) with increasing concentrations of synthetic molecules, and we then performed inhibition SPR by injecting those samples over the sensor surface. Compounds with the CD40 binding motif appended to a macrocyclic core (namely, 1 and 2) competed with binding of hCD40L:CD8 to CD40 in a concentration-dependent manner with a median inhibitory Table 1 ). (g) Compound 1 (125 nM, 250 nM, 500 nM, 1 mM) did not bind to a subset of TNFR family members (B1,000 RU), as shown by SPR. As a control, binding of TNFa to TNFR1 is shown in the leftmost panel.
concentration (IC 50 ) of 78 nM and 50 nM, respectively (Fig. 2a,b) . In contrast, 4, a linear variant of 1 (Fig. 2d) , the cyclic D,L-a-hexapeptide core structure of 1 (R ¼ H, 5; Fig. 2e ) and the monomeric peptide HLys-Gly-Tyr-Tyr-Ahx-OH (6; Fig. 2f ) did not inhibit CD40L binding and therefore served as valuable negative controls. Branched 3 only partially blocked binding of CD40L (20% inhibition at a concentration of 10 mM; Fig. 2c ). We further investigated interaction of our synthetic molecules with CD40 by direct SPR binding experiments. Compounds 1, 2 and, to a lesser extent, 3 bound to CD40 in this assay (Fig. 2a-c and Supplementary Fig. 1 ). Although the binding of the three molecules could be fitted to a simple monovalent binding model, analysis of SPR sensorgrams using a trivalent binding model gave a better fit for 1 and 2 with w 2 values (which describe the closeness of the fit) of 1.34 and 0.97, respectively (Supplementary Table 1 online). This is consistent with the rigid trimeric nature of the chemical CD40 ligands and the dense distribution of the receptor at the surface of the flexible dextran matrix, which could facilitate the formation of tetrameric complexes. The specificity of synthetic mimetics for CD40 is supported by the absence of binding of 1 to other TNFR family members (human TNFR1, TNFR2, LTbR, TRAILR1, EDAR and mouse BCMA, Fig. 2g ).
To establish whether CD40L mimetics 1 and 2 display effector function(s), we used different cell-based assays with soluble CD40L as a positive control. The first test was based on the property of CD40-positive human Burkitt lymphoma cells to undergo apoptosis upon CD40 engagement 24 . Like hCD40L:CD8, but unlike anti-hCD40 mAb 5C3, compounds 1 and 2 induced a dose-dependent apoptosis of Burkitt lymphoma cells (maximal after 16 h of incubation) as measured by the decrease of the mitochondrial membrane potential (Dc m ; Fig. 3a,b) , morphology criteria after DAPI staining (Fig. 3c) , and detection of phosphatidylserine expression (by annexin V staining; Fig. 3d ). The percentage of apoptosis correlated with CD40 expression (Fig. 3b) . Neither control compounds 4-6, which did not interact with CD40, nor branched 3, induced apoptosis (Fig. 3a) , indicating that the ligand architecture markedly influences both the CD40 binding capacity and downstream effector functions, and that distribution of the binding motif in a radial fashion is preferred. Furthermore, singly substituting alanine or glycine for each residue in the CD40 binding sequence in 1 established the importance of Lys143, Tyr145 and Tyr146 residues in both determining binding of 1 ( Supplementary Fig. 2 online) to CD40 and inducing apoptosis of B lymphoma cells (Fig. 3e) .
To verify that CD40L mimetics target CD40 at the surface of lymphoma cells, we synthesized 11, a biotinylated C 3 -symmetric variant of 2 (Fig. 3f) . Like 1 and 2, compound 11 bound to CD40 in SPR experiments and induced Burkitt lymphoma cell apoptosis ( Supplementary Fig. 3 online) . Using colocalization experiments with the anti-hCD40 mAb 5C3 (Fig. 3g) and flow cytometry staining ( Supplementary Fig. 3 ), we found that compound 11 binds to CD40 at the surface of CD40-positive cells but was not detected at the surface of CD40-negative cells. Notably, binding of compound 11 was markedly reduced at 4 1C (Supplementary Fig. 3 ), suggesting that membrane fluidity is required for optimal CD40 binding. Compound 1 also induced apoptosis of mouse CD40-expressing B lymphoma cells (Fig. 4a) . Human and mouse CD40L sequences share 77% identity, and the sequence of the CD40-interacting loop region Lys143-Gly-Tyr-Tyr146 is conserved between both species. This result may suggest that ligands based on this conserved binding motif could also mimic mouse CD40L.
To study the effect of CD40L mimetics on nontransformed cells, purified splenic mouse B cells were treated with CD40L mimetics as well as with a mouse recombinant CD40L (Fc:mCD40L). Whereas Fc:mCD40L at high dose and anti-mouse CD40 mAb 3/23 induced B cell proliferation, compound 1 at 10 mM had no effect on B cell proliferation. However, in a manner analogous to soluble CD40L (ref. 25 ), 1 at 10 mM synergized the proliferation induced by the agonistic anti-mCD40 mAb 3/23 (Fig. 4b) . These results underscore the difference between SPR binding data and cellular assays. On one hand, one can assume that the distribution of CD40 molecules at the surface of the chip significantly differs from that at the cell surface, both qualitatively (in terms of flexibility, accessibility and fluidity) and quantitatively (in terms of density). On the other hand, our findings are in agreement with a number of studies showing that receptor trimerization in the TNFR family is not always sufficient to induce effective signaling and that higher order oligomers are required [24] [25] [26] [27] . Although synthetic ligands based on trimeric architectures probably bound CD40 on B cells by recruiting more than one receptor chain, they might fail to generate sufficient CD40 oligomerization to reach the activation threshold.
Finally, we investigated the capacity of CD40L mimetics to induce DC maturation by using the mouse DC line D1 which matures upon CD40 ligation 28 . Like Fc:mCD40L, compound 1 (5-10 mM) but not compounds 4-6, induced upregulation of MHC and costimulatory molecule expression (Fig. 4c and Supplementary Fig. 4 online) as well as production of interleukin (IL)-12, as visualized by IL-12 p40 mRNA (Fig. 4d) and protein (Supplementary Fig. 4 ) expression. At higher doses (420 mM), maturation was accompanied by cell death. It is noteworthy that the maturation was not decreased in the presence of polymyxin B, an inhibitor of lipopolysaccharide (LPS) LPS activity, thus ruling out the possibility of a CD40-independent, LPS-mediated maturation of D1 cells ( Supplementary Fig. 4) . Moreover, compound 1 activated the NF-kB pathway 29 as shown by the increased degradation of the IkBa protein (Fig. 4e) , suggesting that CD40L mimetics and natural CD40L use the same signaling pathway.
Our results indicate that relatively small (o3 kDa) synthetic trivalent architectures can mimic in vitro the effects of noncovalent signaling protein homotrimers and suggest the possibility of using small CD40 ligands to amplify immune responses in vivo. Extension of the approach to additional TNF members might prove useful to modulate TNFR functions in various pathological situations. Binding of CD40L to CD40. hCD40L:CD8 (Ancell) was injected at a flow rate of 30 ml min -1 over the control channel and the CD40 channel for 5 min and was allowed to dissociate for an additional 5 min. The channels were regenerated for 30 s with 50 mM HCl. Control sensorgrams were subtracted from the CD40 sensorgrams and analyzed by BIAevaluation 4.1 with the 1:1 Langmuir binding model or a trivalent model 30 .
Inhibition of CD40L binding to CD40. hCD40L:CD8 fusion protein was injected at 100 nM (Fig. 2a,b ,d-f) or 200 nM (Fig. 2c) under the same conditions at a flow rate of 10 ml min -1 in the presence of various concentrations of CD40L mimetics. The IC 50 was estimated from the decrease in the initial linear association phase.
Direct binding of the CD40L mimetics. CD40L mimetics were injected at different concentrations under the same conditions. The corrected sensorgrams were analyzed by BIAevaluation 4.1 with binding models as indicated in Supplementary Table 1 Cell culture and apoptosis induction. Burkitt lymphoma (BL41 and Raji), Jurkat human T lymphoma, and 3T6 murine fibroblasts were cultured in RPMI 1640 (Cambrex Bioscience) supplemented with 10% heat-decomplemented fetal bovine serum (FBS) and gentamicin (10 mg ml -1 ). For apoptosis assays, cells (5 Â 10 5 ml -1 ) were incubated at 37 1C in 24-well plates at the indicated times and concentrations in presence of the various inducers. After incubation, cells were washed with PBS before measurement of apoptosis as described above.
Purification and culture of splenic B cells. Spleens were removed from 5-to 12-week-old BALB/c mice. Splenic B cells were prepared by positive selection using magnetic beads coated with anti-CD19 mAb (MACS, Milteny Biotech). This fraction contained more than 95% B220 + cells. B cells (3 Â 10 6 ml -1 )
were then cultured in RPMI 1640 medium supplemented with 10% heatdecomplemented FBS, gentamicin (10 mg ml -1 ), 25 mM HEPES and 10 mM b-mercaptoethanol in the presence of CD40L mimetics, or Fc:mCD40L and/or anti-mouse CD40 mAb (3/23) . Cells were pulsed with [ 3 H]thymidine (1 mCi per well; ICN) during the last 20 h of culture, and [ 3 H]thymidine uptake was measured after 72 h using a Matrix 9600 direct b counter (Packard). The results are given as the arithmetic mean of thymidine uptake expressed as c.p.m.
Culture and maturation of D1 cells. D1 cells were cultured in nontreated plastic dishes in IMDM medium (Cambrex) supplemented with 10% heatdecomplemented FBS, penicillin (100 international units (IU) ml -1 ), 10 mM b-mercaptoethanol, 2 mM L-glutamine and 30% (v/v) of supernatant of NIH/ 3T3 cells as a source of granulocyte-monocyte colony-stimulating factor (GM-CSF). For the maturation assay, 2 Â 10 5 cells ml -1 were cultured for 48 h. Fresh medium containing the various inducers was then added. After various times of incubation, supernatants were collected to measure IL-12 production, and cells were washed with cold PBS and then harvested with 2 ml of PBS containing 2 mM EDTA. After centrifugation, cells were resuspended in cold PBS and analyzed for cell surface phenotyping by flow cytometry or were used for RT-PCR and western blotting analysis as described in Supplementary Methods.
Flow cytometry, confocal microscopy, western blot, RT-PCR and IL-12 measurement. Classical procedures were used. Full experimental procedures are provided in Supplementary Methods.
